Compare SCHL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | CGEM |
|---|---|---|
| Founded | 1920 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.4M | 904.7M |
| IPO Year | 1995 | 2020 |
| Metric | SCHL | CGEM |
|---|---|---|
| Price | $39.40 | $13.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $40.00 | $30.13 |
| AVG Volume (30 Days) | 360.2K | ★ 873.6K |
| Earning Date | 03-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,487,100,000.00 | N/A |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $4.05 | $5.20 |
| P/E Ratio | $20.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.78 | $5.68 |
| 52 Week High | $43.39 | $16.74 |
| Indicator | SCHL | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 45.01 |
| Support Level | $37.70 | $13.75 |
| Resistance Level | $40.22 | $16.21 |
| Average True Range (ATR) | 1.26 | 1.06 |
| MACD | -0.13 | -0.11 |
| Stochastic Oscillator | 61.60 | 20.96 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.